{"entity":{"id":"nct02798406","kind":"trial","name":"Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects","aka":[],"tldr":"A phase 2 trial of DNX-2401 run by DNAtrix, Inc., completed.","summary":"Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects is a phase 2 interventional study registered as NCT02798406 by DNAtrix, Inc., with 49 participants enrolled, started 2016-10-06. Conditions recorded: Brain Cancer, Brain Neoplasm, Glioma, Glioblastoma, Gliosarcoma, Malignant Brain Tumor, Neoplasm, Neuroepithelial, Neuroectodermal Tumors, Neoplasm by Histologic Type, Neoplasm, Nerve Tissue and Nervous System Diseases. Interventions recorded: DNX-2401 and pembrolizumab.","status":"completed","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT02798406","url":"https://clinicaltrials.gov/study/NCT02798406"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["brain-tumours","glioblastoma","metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["dnx-2401"],"companies":["dnatrix"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT02798406","phase":"2","setting":"A Phase II, Multi-center, Open-label Study of a Conditionally Replicative Adenovirus (DNX-2401) With Pembrolizumab (KEYTRUDA®) for Recurrent Glioblastoma or Gliosarcoma (CAPTIVE/KEYNOTE-192)","sponsor":"DNAtrix, Inc.","enrolled":49,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct02798406/","neighbours":{"cancer":[{"id":"brain-tumours","kind":"cancer","name":"Brain and spinal cord tumours (all types)","route":"/cancers/brain-tumours/"},{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"},{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"dnx-2401","kind":"drug","name":"DNX-2401","route":"/drugs/dnx-2401/"}],"company":[{"id":"dnatrix","kind":"company","name":"DNAtrix","route":"/companies/dnatrix/"}]}}